Biocartis, a Lausanne, Switzerland- and Mechelen, Belgium-based molecular diagnostics company developing and commercializing platforms and clinically relevant assays, completed a €30m Series E equity funding.
Backers included existing shareholders such as:
– RMM (Rudi Mariën),
– Debiopharm Diagnostics SA,
– PMV Tina Fund,
– Johnson & Johnson Development Corporation,
– the Wellcome Trust,
– the family offices of Dr. Paul Janssen, Luc Verelst, Rudi Pauwels (founder of Biocartis) and
– smaller shareholders, including some employees.
The company will use the capital to validate its molecular diagnostics platform Idylla[TM] and its first assay and to continue the development of a range of assays, primarily in the oncology field.
Led by Rudi Pauwels, CEO, Biocartis has developed Idylla, a molecular diagnostics platform that allows assays to be performed without the need for a specialist laboratory environment and trained technicians. It and the BRAF cancer assay, which are expected to be launched in the second half of 2014.